Detalles de la búsqueda
1.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916267
2.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298906
3.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363762
4.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(10): 1269-1282, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861273
5.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565
6.
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Ann Hematol
; 98(5): 1217-1224, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30824956
7.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Lancet
; 388(10063): 2997-3005, 2016 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27908454
8.
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Oncologist
; 21(1): 7-15, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26668251
9.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
10.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Invest New Drugs
; 31(5): 1283-93, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23625328
11.
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Lancet Gastroenterol Hepatol
; 8(2): 133-144, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36470291
12.
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open
; 6(4): e235822, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022687
13.
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptorâpositive/human epidermal growth factor receptor 2ânegative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Breast
; 66: 324-331, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36463643
14.
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Eur Urol Oncol
; 5(2): 225-234, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34244116
15.
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
BioDrugs
; 35(3): 337-350, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826080
16.
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Ther Adv Med Oncol
; 13: 17588359211059601, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34917174
17.
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
J Clin Oncol
; 36(10): 968-974, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373094
18.
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 3(12): 845-855, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262136
19.
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Clin Genitourin Cancer
; 15(1): 72-76, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27498023
20.
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Eur J Cancer
; 70: 146-155, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27817944